Inferra AI / Company / SPTX
Seaport Therapeutics, Inc.
SPTX · Health Care
Last earnings Aug 3, 2026
AI analysis
Q1 2026 · reported Jun 8, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The Company considers its convertible preferred stock, prior to conversion upon the Company's IPO, to be participating securities as, in the event a dividend was paid on common stock, the holders of convertible preferred stock would have been entitled to receive dividends on a basis consistent with the common stockholders.
Event summary
Today, we announced new multiple-ascending dose data from this trial, which further reinforce the ability of GlyphAgo TM to achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
The Company considers its convertible preferred stock, prior to conversion upon the Company's IPO, to be participating securities as, in the event a dividend was paid on common stock, the holders of convertible preferred stock would have been entitled to receive dividends on a basis consistent with the common stockholders.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Further, a majority vote of the holders of the Company's Preferred Stock is required to, among others, liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution, or change the authorized number of directors constituting the board of directors.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Dividends The holders of the Preferred Stock are entitled to participate in any dividends payable to common stockholders on an as converted basis and have priority over the payment of dividends to holders of common stock.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
In the case of a dividend on common stock or any class of stock that is convertible into common stock, the dividend per share of Preferred Stock would equal the product of (A) the dividend payable on each share of such class or series as if all shares of such class or series had been converted into common stock and (B) the number of shares of common stock issuable upon conversion of such share of Preferred Stock.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
In the case of a dividend on any class or series that is not convertible into common stock, the dividend per share of Preferred Stock would be determined by (A) dividing the amount of dividend payable on each share of such class or series of capital stock by the original issue price of such class or series and (B) multiplying such fraction by the original issue price of the applicable class or series of Preferred Stock.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Strategy & priorities
About Seaport Therapeutics Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
SEC original ↗Seaport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jun 8, 2026
All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
We must prioritize the development of certain drug product candidates, and these decisions may prove to be wrong and may adversely affect our business.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
, and its consolidated subsidiaries, Seaport or the Company, is a clinical-stage therapeutics company focused on inventing and developing medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders using the Company's proprietary Glyph Platform.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Dividends The holders of the Preferred Stock are entitled to participate in any dividends payable to common stockholders on an as converted basis and have priority over the payment of dividends to holders of common stock.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Risks & headwinds
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics’ business, operating results, financial condition and stock value.
SEC original ↗Seaport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jun 8, 2026
Legal Proceedings 36 Item 1A.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Exhibits 102 Signatures 103 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in " Risk Factor Summary," Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward looking statements as predictions of future events.
SEC original ↗Seaport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
5 documentsEarnings releases
2 documentsPresentations
0 documentsNo presentations for Seaport Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Seaport Therapeutics, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.